Kerin Adelson, MD,

Dr. Adelson on Bortezomib plus Fulvestrant for HR+ Breast Cancer

January 27th 2015

Kerin Adelson, MD, Assistant Professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai, explains the results of a phase II clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.